biostudies-literatureO'Malley GNIDDK NIH HHS245-252https://www.ebi.ac.uk/biostudies/studies/S-EPMC8114941biostudies-literatureUnknown23(4)<b><i>Background:</i></b> Data are limited on the need for and benefits of pump setting optimization with automated insulin delivery. We examined clinical management of a closed-loop control (CLC) system and its relationship to glycemic outcomes. <b><i>Materials and Methods:</i></b> We analyzed personal parameter adjustments in 168 participants in a 6-month multicenter trial of CLC with Control-IQ versus sensor-augmented pump (SAP) therapy. Preset parameters (BR = basal rates, CF = correction factors, CR = carbohydrate ratios) were optimized at randomization, 2 and 13 weeks, for safety issues, participant concerns, or initiation by participants' usual diabetes care team. Time in range (TIR 70-180 mg/dL) was compared in the week before and after parameter changes. <b><i>Results:</i></b> In Diabetes technology & therapeuticsClinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical Trial.PMC8114941P30 DK036836U24 DK123768McCrady-Spitzer SLevy CJPatibandla NEggerman TSlover RDadlani VIsganaitis EFlint ETabatabai IPaulson JACalvo KSimha VBrown SAAmbler-Osborn LLevister CRenard EKeller JBerget CPinsker JEAndre CMurphy CCampos TiDCL Trial Research GroupEmory EJost EJacobson TConshafter KKovatchev BO'Malley GLam DKudva YCReznik YAnderson SKim KKollman DRCRossick-Solis ARaghinaru DBorgman SLaffel LEkhlaspour LMorris KTowers LChurch MMSalas EVoelmle MMitchell HRoethke LPiper MAlonso GTBuckingham BLum JWakeman CMesser LHBreton MOgyaadu SPassman SGreen NForlenza GPCobelli CLovett JOliveri MGondor-Fredrick LTown MArreza-Rubin GWadwa RPReid CKumari KBeck JLRfalseClinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical Trial.<b><i>Background:</i></b> Data are limited on the need for and benefits of pump setting optimization with automated insulin delivery. We examined clinical management of a closed-loop control (CLC) system and its relationship to glycemic outcomes. <b><i>Materials and Methods:</i></b> We analyzed personal parameter adjustments in 168 participants in a 6-month multicenter trial of CLC with Control-IQ versus sensor-augmented pump (SAP) therapy. Preset parameters (BR = basal rates, CF = correction factors, CR = carbohydrate ratios) were optimized at randomization, 2 and 13 weeks, for safety issues, participant concerns, or initiation by participants' usual diabetes care team. Time in range (TIR 70-180 mg/dL) was compared in the week before and after parameter changes. <b><i>Results:</i></b> In 2021-01-01T00:00:00Z2021 Apr2025-04-04T23:03:10.336Z2025-02-18T23:32:28.498ZS-EPMC81149413315582410.1089/dia.2020.0472